These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 7592913

  • 41. Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth.
    Bredel M, Pollack IF, Freund JM, Hamilton AD, Sebti SM.
    Neurosurgery; 1998 Jul; 43(1):124-31; discussion 131-2. PubMed ID: 9657198
    [Abstract] [Full Text] [Related]

  • 42. [Inhibitors of isoprenylation of ras p21].
    Yoshimatsu K.
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
    [Abstract] [Full Text] [Related]

  • 43. Genetic evidence for in vivo cross-specificity of the CaaX-box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase-I in Saccharomyces cerevisiae.
    Trueblood CE, Ohya Y, Rine J.
    Mol Cell Biol; 1993 Jul; 13(7):4260-75. PubMed ID: 8321228
    [Abstract] [Full Text] [Related]

  • 44. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
    Morgan MA, Wegner J, Aydilek E, Ganser A, Reuter CW.
    Leukemia; 2003 Aug; 17(8):1508-20. PubMed ID: 12886237
    [Abstract] [Full Text] [Related]

  • 45. Synthesis and biological activity of semipeptoid farnesyltransferase inhibitors.
    Reuveni H, Gitler A, Poradosu E, Gilon C, Levitzki A.
    Bioorg Med Chem; 1997 Jan; 5(1):85-92. PubMed ID: 9043660
    [Abstract] [Full Text] [Related]

  • 46. Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions.
    Tamanoi F, Lu J.
    Enzymes; 2013 Jan; 34 Pt. B():181-200. PubMed ID: 25034105
    [Abstract] [Full Text] [Related]

  • 47. Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298.
    Allal C, Pradines A, Hamilton AD, Sebti SM, Favre G.
    Cell Cycle; 2002 Jan; 1(6):430-7. PubMed ID: 12548020
    [Abstract] [Full Text] [Related]

  • 48. The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.
    O'Meara SJ, Kinsella BT.
    Biochem J; 2005 Feb 15; 386(Pt 1):177-89. PubMed ID: 15469414
    [Abstract] [Full Text] [Related]

  • 49. Disrupting the transforming activity of shrimp ras(Q(61)K) by deleting the CAAX box at the C-terminus.
    Huang CF, Chen CH, Chuang NN.
    J Exp Zool; 2001 Jun 01; 289(7):441-8. PubMed ID: 11351331
    [Abstract] [Full Text] [Related]

  • 50. Amino acid residues that define both the isoprenoid and CAAX preferences of the Saccharomyces cerevisiae protein farnesyltransferase. Creating the perfect farnesyltransferase.
    Caplin BE, Ohya Y, Marshall MS.
    J Biol Chem; 1998 Apr 17; 273(16):9472-9. PubMed ID: 9545274
    [Abstract] [Full Text] [Related]

  • 51. Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I.
    Chan LN, Fiji HD, Watanabe M, Kwon O, Tamanoi F.
    PLoS One; 2011 Apr 17; 6(10):e26135. PubMed ID: 22028818
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Pharmacological modulation of geranylgeranyltransferase and farnesyltransferase attenuates opioid withdrawal in vivo and in vitro.
    Rehni AK, Singh TG.
    Neuropharmacology; 2013 Aug 17; 71():19-26. PubMed ID: 23415632
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
    End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C.
    Cancer Res; 2001 Jan 01; 61(1):131-7. PubMed ID: 11196150
    [Abstract] [Full Text] [Related]

  • 57. Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras.
    Novotny CJ, Hamilton GL, McCormick F, Shokat KM.
    ACS Chem Biol; 2017 Jul 21; 12(7):1956-1962. PubMed ID: 28530791
    [Abstract] [Full Text] [Related]

  • 58. Protein Geranylgeranyltransferase Type 1 as a Target in Cancer.
    Ullah N, Mansha M, Casey PJ.
    Curr Cancer Drug Targets; 2016 Jul 21; 16(7):563-71. PubMed ID: 26648485
    [Abstract] [Full Text] [Related]

  • 59. Reversal of the Ras-induced transformed phenotype by HR12, a novel ras farnesylation inhibitor, is mediated by the Mek/Erk pathway.
    Reuveni H, Geiger T, Geiger B, Levitzki A.
    J Cell Biol; 2000 Dec 11; 151(6):1179-92. PubMed ID: 11121434
    [Abstract] [Full Text] [Related]

  • 60. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner.
    Yonemoto M, Satoh T, Arakawa H, Suzuki-Takahashi I, Monden Y, Kodera T, Tanaka K, Aoyama T, Iwasawa Y, Kamei T, Nishimura S, Tomimoto K.
    Mol Pharmacol; 1998 Jul 11; 54(1):1-7. PubMed ID: 9658183
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.